Company Oncology Venture A/S Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
24/05 | Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial | CI |
14/05 | Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21/21/21 |
Chief Tech/Sci/R&D Officer | 63 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 01/22/01 | |
Thomas Jensen
FOU | Founder | 46 | 01/20/01 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01/23/01 |
Laura Benjamin
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,606,739 | 17,606,681 ( 100.00 %) | 0 | 100.00 % |
Stock B | 0 | 1,215 | 0 | 0 |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ALLR Stock
- Stock
- Company Oncology Venture A/S